JonesTrading analyst Prakhar Agrawal maintained a Buy rating on Arena Pharmaceuticals on Wednesday, setting a price target of $94, which is approximately 34.88% above the present share price of $69.69.
Agrawal expects Arena Pharmaceuticals to post earnings per share (EPS) of -$1.98 for the third quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Arena Pharma (NASDAQ:ARNA), with an average price target of $100.29.
The analysts price targets range from a high of $120 to a low of $80.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $0 and a net profit of -$132.04 million. The company's market cap is $4.23 billion.
According to TipRanks.com, JonesTrading analyst Prakhar Agrawal is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.1% and a 26.92% success rate.
Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.